At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Metabolism-informed Care for Smoking Cessation
In Brief
A clinical study evaluating Nicotine Metabolite Ratio, Varenicline, and 2 other interventions for Tobacco Use and Tobacco Use Cessation. Completed, enrolled 82 participants.
Detailed Summary
Nicotine mediates smoking's addictive effects in the brain. The ratio of 3-hydroxycotinine to cotinine, known as the nicotine metabolite ratio, or NMR, is a genetically- informed biomarker reflecting hepatic CYP2A6 activity and the rate of nicotine metabolism. In light of a recent randomized controlled trial (RCT) in humans in Lancet Respiratory Medicine, which found that the NMR can be used to individualize treatment for smokers, our pilot study aims to determine the feasibility of using NMR to guide selection of pharmacotherapy in clinical populations of daily smokers.
Study Details
Timeline
Interventions
This intervention used information from a genetically-informed biomarker (Nicotine Metabolite Ratio, NMR) to assign one of 3 FDA-approved smoking cessation pharmacotherapies (varenicline, bupropion, or NRT) to participants.
FDA-approved smoking cessation pharmacotherapy
FDA-approved smoking cessation pharmacotherapy
FDA-approved smoking cessation pharmacotherapy